| Authors: |
Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Wei Z; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Davies MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Gray RJ; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, CA., Liu R; Department of Hematology Oncology, The Permanente Medical Group, San Francisco, CA., Bota DA; UCI Health Chao Family Comprehensive Cancer Center, Orange, CA., Swiecicki PL; University of Michigan Rogel Cancer Center, Ann Arbor, MI., Buchschacher GL; Kaiser Permanente Southern California, Los Angeles, CA., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; UT Southwestern Simmons Cancer Center, Dallas, TX., Arteaga CL; UT Southwestern Simmons Cancer Center, Dallas, TX., Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA. |
